脑出血合并房颤复发卒中的神经影像标志物:PRESTIGE-AF二次分析
PRESTIGE-AF试验纳入319例自发性脑出血合并房颤患者,其中313例有足够质量的神经影像。中位随访1.4年,13例复发脑出血、22例缺血性卒中。皮质表面铁沉积和慢性脑内大出血与复发脑出血风险增加相关,非脑叶出血与缺血性卒中风险增加相关。
要点
- 皮质表面铁沉积患者复发脑出血风险显著增加(HR 7.7)。
- 慢性脑内大出血患者复发脑出血风险显著增加(HR 9.1)。
- 非脑叶脑出血患者缺血性卒中风险增加(HR 9.1)。
核心结论
- 神经影像有助于识别脑出血合并房颤患者中复发脑出血或缺血性卒中风险特别高的人群,强调其在临床决策中的作用。
研究设计与样本
- PRESTIGE-AF为前瞻性随机临床试验,在6个欧洲国家75家医院开展,319例自发性脑出血合并房颤患者随机接受直接口服抗凝药或不抗凝治疗。
- 预设影像亚分析集中评估基线脑CT和MRI,采用既定评分和定义,313例影像质量足够,其中170例(54.3%)有MRI。
- 采用Cox回归分析神经影像发现与复发脑出血和缺血性卒中的关联。
主要发现
- 中位随访1.4年,13例复发脑出血,22例缺血性卒中。
- 复发脑出血与脑叶vs非脑叶血肿位置或很可能脑淀粉样血管病总体分类无关(p > 0.2)。
- 皮质表面铁沉积患者复发脑出血风险增加(HR 7.7,95% CI 1.4-42.2)。
- MRI显示慢性脑内大出血患者复发脑出血风险增加(HR 9.1,95% CI 1.8-46.8)。
- 非脑叶脑出血患者缺血性卒中风险增加(HR 9.1,95% CI 1.2-67.7)。
临床怎么用
- 对脑出血合并房颤患者,可利用MRI评估皮质表面铁沉积和慢性脑内大出血等标志物,辅助个体化风险分层。
- 非脑叶脑出血患者缺血性卒中风险较高,临床决策时需权衡抗凝获益与复发脑出血风险。
局限性
- 主要局限性为结局事件数量较少,需要在更大规模合作中验证 findings。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Anticoagulation in patients with intracerebral hemorrhage (ICH) and atrial fibrillation reduces the risk of ischemic stroke (IS), but also potentially causes an excess risk of recurrent ICH. In this context, we assessed the role of neuroimaging in identifying patients with particular susceptibility to IS or ICH, potentially allowing for individualized risk stratification. METHODS: In PRESTIGE-AF, a prospective, randomized clinical trial conducted across 75 hospitals in 6 European countries, participants with spontaneous ICH and atrial fibrillation were randomized to treatment with direct oral anticoagulants or no anticoagulation. Within a prespecified imaging subanalysis, we centrally assessed brain CT and MRI scans at baseline using established scales and definitions. We performed Cox regression analyses to investigate associations of neuroimaging findings with recurrent ICH and IS. RESULTS: PRESTIGE-AF included 319 patients, and 313 had neuroimaging of sufficient quality (median age 79 years, 35.5% female). MRI was available in 170 patients (54.3%). During a median follow-up of 1.4 years, 13 patients had recurrent ICH and 22 patients had IS. ICH recurrence was not associated with lobar vs nonlobar hematoma location or the overall category of probable cerebral amyloid angiopathy (p > 0.2). However, there was an increased risk of recurrent ICH in patients with cortical superficial siderosis (hazard ratio [HR] 7.7, 95% CI 1.4-42.2) and chronic intracerebral macrohemorrhages on MRI (HR 9.1, 95% CI 1.8-46.8). Patients with nonlobar ICH were at increased risk of IS (HR 9.1, 95% CI 1.2-67.7). DISCUSSION: Neuroimaging contributes to the identification of patients with ICH and atrial fibrillation at particularly high risk of recurrent ICH or IS, emphasizing its role in clinical decision making. MRI allows for the assessment of relevant neuroimaging markers that can aid the risk assessment in affected patients. Major study limitations include the modest number of outcome events, with confirmation of our findings needed in larger collaborations. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov NCT03996772; first submitted June 21, 2019; first patient enrolled: May 31, 2019; available at clinicaltrials.gov/study/NCT03996772.
引用
- Fandler-Höfler S, Ropele S, Gattringer T, et al. Neuroimaging Markers Associated With Recurrent Stroke in Intracerebral Hemorrhage and Atrial Fibrillation: Secondary Analysis of PRESTIGE-AF. Neurology. 2025. PMID: 41197104. doi:10.1212/WNL.0000000000214386
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。